Infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), is widely used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease (CD), and UC. This evidence concerns the gene TNF and autoimmune disease.